Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MTSR

Metsera Inc

Mar 21 • 04:00PM ET

28.02

Dollar change +0.20
Percentage change 0.72	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VB VBR VBK ONEQ RSSL HRTS UWM URTY VXF

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	42.81%	Shs Outstand	103.04M	Perf Week	11.15%
Market Cap	2.95B	Forward P/E	-	EPS next Y	-3.28	Insider Trans	13.13%	Shs Float	60.23M	Perf Month	-11.44%
Income	-	PEG	-	EPS next Q	-0.87	Inst Own	1.76%	Short Float	6.97%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	35.03%	Inst Trans	39.49%	Short Ratio	5.97	Perf Half Y	-
Book/sh	-0.44	P/B	-	EPS next Y	-16.15%	ROA	-	Short Interest	4.20M	Perf Year	-
Cash/sh	0.71	P/C	39.25	EPS next 5Y	2.70%	ROE	-	52W Range	23.08 - 32.81	Perf YTD	5.74%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-14.59%	Beta	-
Dividend TTM	-	Quick Ratio	3.81	Sales past 5Y	0.00%	Gross Margin	-	52W Low	21.40%	ATR (14)	2.27
Dividend Ex-Date	-	Current Ratio	3.81	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	53.25	Volatility	9.91% 8.93%
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	47.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	5.70	Prev Close	27.82
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	703.07K	Price	28.02
SMA20	4.05%	SMA50	-0.90%	SMA200	-0.90%	Trades		Volume	4,006,083	Change	0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-25-25	Initiated	Guggenheim	Buy	$56
Feb-25-25	Initiated	Evercore ISI	Outperform
Feb-25-25	Initiated	BofA Securities	Buy	$38

Mar-15-25 04:42PM	Metsera, Inc. (MTSR): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-06-25 10:13AM	Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Mar-03-25 02:50PM	Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey) +15.01%
Mar-01-25 05:02AM	Q4 2024 Amneal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 07:00AM	Metsera to Present at TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
02:04PM	Loading…
Feb-25-25 02:04PM	Wall Street bullish on Metsera following January IPO on obesity drug pipeline (Investing.com) -8.32%
Feb-19-25 02:50PM	Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently (Insider Monkey)
Feb-05-25 04:01PM	Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
06:53PM	Metsera Announces Pricing of Initial Public Offering (GlobeNewswire)
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burow Kristina	Director	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:15 PM
BERNS PAUL L	Director	Feb 03 '25	Buy	18.00	789,998	14,219,964	8,313,680	Feb 03 07:04 PM
ARCH Venture Partners XII, LLC	10% Owner	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MTSR

Metsera Inc

Upgrade your FINVIZ experience